Contineum Therapeutics (CTNM) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

CTNM · Stock Price

USD 14.63+10.76 (+278.04%)

Market Cap: $545.8M

Historical price data

Market Cap: $545.8MPipeline: 8 drugsPatents: 2Founded: 2021Employees: 11-50HQ: San Diego, United States

Sector Ranking#205 in Small Molecule Drugs #36 in Neuroscience & CNS

Overview

Contineum Therapeutics is a public, clinical-stage biotech (NASDAQ: CTNM) with a mission to develop oral, small molecule drugs for neuroinflammatory and fibrotic diseases. Its strategy leverages human genetic validation of specific GPCR targets, most notably the M1 muscarinic and LPA1 receptors, to derisk development and address large patient populations. Key achievements include advancing its lead asset, PIPE-307, to Phase 2 in multiple sclerosis and depression, and progressing a second key asset, PIPE-791, through Phase 1 for idiopathic pulmonary fibrosis and progressive MS. The company operates with a lean, virtual structure, utilizing strategic partnerships and CROs to advance its pipeline efficiently.

NeuroscienceImmunologyInflammation

Technology Platform

Mechanism-based drug discovery focused on designing oral, small molecule modulators of biologically validated GPCR targets, with expertise in achieving blood-brain barrier penetration for CNS applications.

Pipeline

8

8 drugs in pipeline

Drug	Indication	Stage
PIPE-307 Dose A + PIPE-307 Dose B + Placebo	Relapsing Remitting Multiple Sclerosis	Phase 2
PIPE-791 Dose A + PIPE-791 Dose B + Placebo	Idiopathic Pulmonary Fibrosis	Phase 2
PIPE-505 + Placebo	Sensorineural Hearing Loss	Phase 1/2
PIPE-307	Multiple Sclerosis	Phase 1
PIPE-791 + Placebo	Chronic Osteoarthritis Pain	Phase 1

Funding History

2

Total raised:$190M

Series B$110MBristol Myers SquibbApr 15, 2023

Series A$80MPfizerJan 15, 2022

Opportunities

Contineum has near-term catalysts with Phase 2 data for PIPE-307 in MS (H2 2025) that could significantly derisk its lead asset and validate its platform.

The dual development of PIPE-791 in IPF and progressive MS provides two shots on goal in large, underserved markets with a mechanistically distinct approach.

A strong cash runway into 2027 provides ample time to reach key value inflection points without immediate dilution.

Risk Factors

The company faces high clinical development risk, as negative Phase 2 data for PIPE-307 would severely impact valuation.

It operates in highly competitive markets (MS, IPF, MDD) against established standards of care, creating commercial adoption challenges.

As a pre-revenue company, it remains dependent on capital markets for future funding beyond its current runway.

Competitive Landscape

Contineum's lead programs face established and novel competitors. In MS, PIPE-307 competes with high-efficacy biologics and oral agents like BTK inhibitors, differentiating on its unique M1 mechanism. In IPF, PIPE-791 will compete against approved anti-fibrotics and Bristol Myers Squibb's late-stage LPA1 antagonist, requiring strong efficacy data. Its success hinges on demonstrating clear clinical differentiation in upcoming trials.